|本期目录/Table of Contents|

[1]袁晓芳,刘一鸣,赵茜.预防性使用重组人粒细胞刺激因子对神经母细胞瘤患儿化疗后骨髓抑制的影响[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):247-250.[doi:10.3969/j.issn.1672-271X.2023.03.005]
　YUAN Xiaofang,LIU Yiming,ZHAO Qian.Effects of prophylactic use of recombinant human granulocyte colony stimulating factor on myelosuppression in children with neuroblastoma after chemotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(3):247-250.[doi:10.3969/j.issn.1672-271X.2023.03.005]
点击复制

预防性使用重组人粒细胞刺激因子对神经母细胞瘤患儿化疗后骨髓抑制的影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年3期
页码:
247-250
栏目:
临床研究
出版日期:
2023-08-01

文章信息/Info

Title:
Effects of prophylactic use of recombinant human granulocyte colony stimulating factor on myelosuppression in children with neuroblastoma after chemotherapy
作者:
袁晓芳; 刘一鸣; 赵茜
作者单位：210008南京，南京医科大学附属儿童医院肿瘤外科（袁晓芳、刘一鸣、赵茜）
Author(s):
YUAN Xiaofang;  LIU Yiming;  ZHAO Qian
(Department of Surgical Oncology, Children’s Hospital Affiliated to Nanjing Medical University, Nanjing 210008, Jiangsu, China)
关键词:
重组人粒细胞刺激因子; 神经母细胞瘤; 骨髓抑制; 化疗
Keywords:
recombinant human granulocyte colony stimulating factor; neuroblastoma; myelosuppression; chemotherapy
分类号:
R739.4
DOI:
10.3969/j.issn.1672-271X.2023.03.005
文献标志码:
A
摘要:
目的探究预防性使用重组人粒细胞刺激因子（rhG-CSF）对神经母细胞瘤（NB）患儿化疗后骨髓抑制的影响。方法选取2020年6月-2022年7月在南京医科大学附属儿童医院确诊的66例NB患儿，采用随机数表法将NB患儿分为预防组（33例）和对照组（33例）。2组患儿第一化疗周期均采用环磷酰胺+托泊替康的化疗方案，预防组在化疗开始24~48 h后立即预防性使用rhG-CSF，对照组在出现粒细胞缺乏后再给予rhG-CSF进行治疗。比较预防组和对照组患儿白细胞计数（WBC）、中性粒细胞绝对计数（ANC）、干扰素-γ（IFN-γ）、肿瘤坏死因子-α（TNF-α）水平和WBC、ANC 恢复正常的时间，观察2组患儿继发感染发生率和不良反应发生率。结果治疗后，预防组WBC、ANC水平分别为（5.65±2.41）×109/L、（6.22±2.34）×109/L，均高于对照组的（3.91±2.32）×109/L、（4.45±1.12）×109/L，差异有统计学意义（P＜0.05）；预防组IFN-γ、TNF-α水平分别为（6.91±1.41）μg/L、（12.22±2.34）ng/L，低于对照组的（10.42±2.12）μg/L、（19.45±1.62）ng/L，差异有统计学意义（P＜0.05）；预防组WBC、ANC恢复正常时间分别为（5.56±0.86）d、（5.52±0.82）d，均短于对照组的（7.21±1.21）d、（7.43±1.25）d，差异有统计学意义（P＜0.05）；预防组继发感染发生率（21.21%）低于对照组（46.88%），差异有统计学意义（P＜0.05）。2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论rhG-CSF能改善NB患儿化疗后引起的骨髓抑制，预防性使用更能明显减轻NB化疗后骨髓抑制，减少继发性感染，具有一定的临床预后改善价值。
Abstract:
ObjectiveTo explore the effects of prophylactic use of recombinant human granulocyte colony stimulating factor (rhG-CSF) on myelosuppression in children with neuroblastoma (NB) after chemotherapy.MethodsA total of 66 children with NB confirmed in the hospital were enrolled between June 2020 and July 2022. According to random number table method, they were divided into prevention group (33 cases) and control group (33 cases). During the first chemotherapy, both groups were given the chemotherapy regimen (cyclophosphamide + topotecan). The prevention group was given prophylactic use of rhG-CSF immediately after 24-48h of chemotherapy, while control group was given rhG-CSF after agranulocytosis. The levels of white blood cell count (WBC), absolute neutrophil count (ANC), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), recovery time of WBC and ANC in the two groups were compared. The incidence of secondary infection and adverse reactions in both groups was observed.ResultsAfter treatment, levels of WBC and ANC in prevention group were (5.65±2.41) ×109/L and (6.22±2.34) ×109/L, higher than those in control group [(3.91±2.32) ×109/L, (4.45±1.12) ×109/L, P<0.05]. The levels of IFN-γ and TNF-α in prevention group were (6.91±1.41) μg/L and (12.22±2.34) ng/L, lower than those in control group [(10.42±2.12) μg/L, (19.45±1.62) ng/L, P<0.05].The recovery time of WBC and ANC in prevention group was (5.56±0.86)d and (5.52±0.82)d, shorter than that in control group [(7.21±1.21)d, (7.43±1.25)d, P<0.05]. The incidence of secondary infection in prevention group was lower than that in control group (21.21%vs 46.88%, P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).ConclusionThe rhG-CSF can improve myelosuppression in NB after chemotherapy.The prophylactic useof rhG-CSF can more significantly relieve myelosuppression and reduce secondary infection, with certain clinical prognostic value.

参考文献/References:

[1]Chung C, Boterberg T, Lucas J,et al. Neuroblastoma[J]. Pediatr Blood Cancer, 2021,68(Suppl 2):e28473.
[2]Geurten C,Geurten M,Hoyoux C,et al. Endocrine consequences of neuroblastoma treatment in children:20 years’ experience of a single center[J]. J Pediatr Endocrinol Metab,2019,32(4):347-354.
[3]Herd F,Basta NO,McNally RJQ,et al. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma[J]. Eur J Cancer,2019,4(111):50-58.
[4]Utriainen P,Vatanen A,Toiviainen-Salo S,et al. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue[J]. Bone Marrow Transplant,2017,52(5)：711-716.
[5]于凯璇,周延民.放疗对骨组织及种植体周围骨结合影响的研究进展[J].口腔医学研究,2020,36(3):209-212.
[6]万露露,唐锁勤,刘英,等. 重组人粒细胞刺激因子在晚期儿童神经母细胞瘤化疗后早期预防性应用的疗效观察[J]. 解放军医学院学报,2019,40(8):753-756.
[7]中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤学组. 儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案[J]. 中华小儿外科杂志,2022,43(7):588-598.
[8]美国东部肿瘤协作组 . 抗癌药急性及亚急性毒性反应分度标准（WHO 标准）[J]. 癌症，1992,7(3):280.
[9]孙家栋,李雪梅,刘君玲.CYLD基因对神经母细胞瘤凋亡和活性氧水平及NF-κB信号的影响[J].医学研究生学报,2021,34(8):798-801.
[10]Keyel ME, Reynolds CP.Spotlight on dinutuximab in the treatment ofhigh-risk neuroblastoma:development andplace in therapy[J].Biologics,2018，13:1-12.
[11]倪春霞,王宝红,吴学勇,等. 顺铂联合替莫唑胺放化疗治疗MGMT启动子未甲基化胶质母细胞瘤的初步研究[J]．临床神经外科杂志,2019,16(1):6-10,16.
[12]周政荣,刘珊珊. 重组人粒细胞刺激因子剂量对Ⅳ度骨髓抑制的癌症化疗患者免疫功能影响研究[J]. 黑龙江医学,2022,46(10):1213-1215.
[13]罗杰美. rhG-CSF预防性疗法对乳腺癌化疗患者骨髓抑制的影响分析[J]. 基层医学论坛,2022,26(1):135-137.
[14]曲隽渊,李炘正,张华一,等. 不同重组人粒细胞刺激因子对乳腺癌化疗后骨髓抑制的防治观察[J].中国药物与临床,2019,19(24):4299-4301.
[15]陈东玉,臧玉柱.重组人粒细胞刺激因子注射液对白血病化疗患者骨髓抑制及外周血象的影响[J].内蒙古医学杂志,2020,52(1):68-70.
[16]张崇阳.恶性肿瘤化疗致中性粒细胞缺乏症治疗方案及疗效分析[J].中国社区医师,2019,35(36):49,51.
[17]Zhang JY,Liu YX,Wang H,et al. The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor（PEG-rhG-CSF） in breast cancer receiving adjuvant chemotherapy[J]. Zhonghua Yi Xue Za Zhi，2018,98(34):2718-2721.
[18]Okuda Y,Mori M,Shinada M,et al. Examination of Fever Risk Factors after Prophylaxis with G-CSF[J]. Gan To Kagaku Ryoho,2018,45(10):1431-1434.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：中国博士后基金面上项目(2020M671550）
更新日期/Last Update: 2023-08-24